Table 2.
The most promising MHC class I-related peptides in the envelope protein-based vaccine of COVID-19 along with the predicted coverage of the world, China, Europe, and East Asia.
| Peptide | Alleles | Coverage | Combined coverage of 10 peptides |
|---|---|---|---|
| YVYSRVKNL | HLA-C∗14:02, HLA-C∗12:03, HLA-C∗07:01, HLA-C∗03:03, HLA-C∗06:02 | 50.02% | World: 88.5% |
| SLVKPSFYV | HLA-A∗02:06, HLA-A∗02:01, HLA-A∗68:02 | 42.53% | China: 78.17% |
| SVLLFLAFV | HLA-A∗02:06, HLA-A∗68:02, HLA-A∗02:01 | 42.53% | Europe: 92.94% |
| FLAFVVFLL | HLA-A∗02:01, HLA-A∗02:06 | 40.60% | East Asia: 80.78% |
| VLLFLAFVV | HLA-A∗02:01 | 39.08% | |
| RLCAYCCNI | HLA-A∗02:01 | 39.08% | |
| FVSEETGTL | HLA-C∗03:03, HLA-C∗12:03, HLA-A∗02:06, HLA-A∗68:02, HLA-B∗35:01 | 28.22% | |
| LTALRLCAY | HLA-A∗01:01, HLA-A∗30:02, HLA-B∗15:01 | 26.34% | |
| LVKPSFYVY | HLA-B∗15:01, HLA-A∗29:02, HLA-A∗30:02, HLA-B∗35:01 | 21.72% | |
| NIVNVSLVK | HLA-A∗68:01, HLA-A∗11:01 | 20.88% |